{"organizations": [], "uuid": "bc4c0df15f0a2059b19e6fcdcc140d661fd3e9c2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-pfizer-says-us-eu-and-japan-health/brief-pfizer-says-u-s-eu-and-japan-health-authorities-accept-lorlatinib-for-review-idUSFWN1Q20U1", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.465, "site_type": "news", "published": "2018-02-12T21:07:00.000+02:00", "replies_count": 0, "uuid": "bc4c0df15f0a2059b19e6fcdcc140d661fd3e9c2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-pfizer-says-us-eu-and-japan-health/brief-pfizer-says-u-s-eu-and-japan-health-authorities-accept-lorlatinib-for-review-idUSFWN1Q20U1", "ord_in_thread": 0, "title": "BRIEF-Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review", "locations": [], "entities": {"persons": [{"name": "brief-pfizer", "sentiment": "negative"}], "locations": [{"name": "eu", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "pfizer inc", "sentiment": "negative"}, {"name": "eu and japan health authorities", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "lorlatinib", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Pfizer Inc:\n* U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZERâ€™S THIRD-GENERATION ALK INHIBITOR LORLATINIB\n* PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T21:07:00.000+02:00", "crawled": "2018-02-13T15:52:39.045+02:00", "highlightTitle": ""}